CytomX Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: CytomX Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q3 2024.
CytomX Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -612 %, a 52.9% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	-612	-212	-52.9%	Sep 30, 2024
Q2 2024	-575	-199	-53%	Jun 30, 2024
Q1 2024	-479	-59.8	-14.3%	Mar 31, 2024
Q4 2023	-421	+96.2	+18.6%	Dec 31, 2023
Q3 2023	-400	+379	+48.7%	Sep 30, 2023
Q2 2023	-376	+2.06K	+84.6%	Jun 30, 2023
Q1 2023	-419	-2.74K	-118%	Mar 31, 2023
Q4 2022	-517	-1.33K	-163%	Dec 31, 2022
Q3 2022	-779	-1.65K	-190%	Sep 30, 2022
Q2 2022	-2.43K	-3.21K	-413%	Jun 30, 2022
Q1 2022	2.32K	+1.54K	+199%	Mar 31, 2022
Q4 2021	817	-14.5	-1.75%	Dec 31, 2021
Q3 2021	870	+213	+32.5%	Sep 30, 2021
Q2 2021	777	+230	+42.1%	Jun 30, 2021
Q1 2021	774	+325	+72.4%	Mar 31, 2021
Q4 2020	831	+468	+129%	Dec 31, 2020
Q3 2020	657	+376	+134%	Sep 30, 2020
Q2 2020	547	+300	+122%	Jun 30, 2020
Q1 2020	449	+162	+56.7%	Mar 31, 2020
Q4 2019	364	+21.8	+6.38%	Dec 31, 2019
Q3 2019	281	-132	-32%	Sep 30, 2019
Q2 2019	247	-399	-61.8%	Jun 30, 2019
Q1 2019	286	-310	-52%	Mar 31, 2019
Q4 2018	342	-103	-23.1%	Dec 31, 2018
Q3 2018	413	+66.8	+19.3%	Sep 30, 2018
Q2 2018	646	+432	+202%	Jun 30, 2018
Q1 2018	596	+470	+371%	Mar 31, 2018
Q4 2017	445	+337	+315%	Dec 31, 2017
Q3 2017	346	+263	+314%	Sep 30, 2017
Q2 2017	214	+73.5	+52.4%	Jun 30, 2017
Q1 2017	127			Mar 31, 2017
Q4 2016	107			Dec 31, 2016
Q3 2016	83.7			Sep 30, 2016
Q2 2016	140			Jun 30, 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.